HOME Press Releases High Potency API /HPAPI Market worth 24.09 Billion USD by 2021



High Potency API /HPAPI Market worth 24.09 Billion USD by 2021


The report "High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

     Download PDF Brochure     Speak to Analyst     Inquiry Before Buying

Browse 221 market data tables and 44 figures spread through 214 pages and in-depth TOC on “High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021”
http://www.marketsandmarkets.com/Market-Reports/high-potency-api-market-36582475.html
Early buyers will receive 10% customization on reports.

The global high potency active pharmaceutical ingredients (HPAPI) market is expected to reach USD 24.09 Billion by 2021 from USD 16.02 Billion in 2016, growing at a CAGR of 8.5% from 2016 to 2021.

On the basis of type, the high potency active pharmaceutical ingredients market is segmented into innovative and generic HPAPIs. The innovative HPAPIs segment is estimated to account for the larger share of the total HPAPIs market. The large share of this segment is attributed to the presence of large number of patent-protected innovative HPAPIs, their higher price as compared to generics, growing focus of major players on the development of novel high-potency products, and the growing demand for novel high-potency cancer therapeutics. On the basis of type of manufacturer, the high potency active pharmaceutical ingredients market is segmented into captive and merchant HPAPI manufacturers.

The HPAPIs market, on the basis of type of synthesis, is segmented into synthetic and biotech HPAPIs. Synthetic HPAPIs is estimated to dominate this market in 2016.The large share of this segment can be attributed to the increasing emergence of new molecules in the market, rising number of new product approvals, technological advancements in synthesis, and ease of production. However, the biotech APIs market is expected to grow at a substantially higher rate during the forecast period owing to Advances in biotechnology, growing demand for antibody drug conjugates, growing demand due to their specificity in action, their similarity with the natural biological compounds, and significant growth in the demand for monoclonal antibodies.

Based on therapeutic application, the high potency active pharmaceutical ingredients market is segmented into oncology, hormonal imbalance, glaucoma, and other therapeutic applications. The oncology segment is estimated to account for the largest share of the global HPAPIs market in 2016. The growing incidence and prevalence of cancer across the globe and the launch of new target therapies in addition to technological advancements in the oncology HPAPI-antibody conjugate technology are major factors contributing to the growth of this application segment.

Based on geography, the global high potency active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to various factors growing incidence of cancer, increasing investments in cancer research especially targeted therapies, increasing demand for cancer HPAPIs, technological advancements in HPAPI manufacturing, growing CMOs market.

Prominent players in the high potency active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports